Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Bevacizumab + Temozolomide in Recurrent Glioblastoma
NCT05638451Phase 2Unknown
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- May 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in glioblastoma (GBM), sponsored by Southern Medical University Zhujiang Hospital. Status: unknown.
02
Drugs
sintilimab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05638451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638451.